Ionis Pharmaceuticals, the leader in RNA-targeted drug discovery and development, has today announced the appointment of Onaiza Cadoret-Manier as chief corporate development and commercial officer reporting to CEO Brett P. Monia. In this newly created role, Ms. Cadoret-Manier will serve as a member of Ionis' executive leadership team and be responsible for corporate strategy, commercialization, and operational leadership.
Ms. Cadoret-Manier is a life sciences industry veteran, with 30 years of experience driving growth for start-up to Fortune 500 companies.
"Ms. Cadoret-Manier's appointment is a very significant addition to the Ionis leadership team. Her years of diverse experience and success are ideal as we work towards new areas of corporate growth and investment," said Dr. Monia. "I'm positive that her strength in commercialization and strategic planning will prove to be invaluable and play an important part in shaping the next chapter for Ionis."